ProCE Banner Activity

Current and Emerging Roles of BTK Inhibitors in CLL/SLL and MCL

Slideset

Slides featuring expert perspective on caring for patients with CLL/SLL and MCL, including clinical evidence supporting current standard of care, strategies for selecting the appropriate BTK inhibitors based on current indications, recognizing key patient and disease factors informing therapy, and management of BTK inhibitor-related adverse events.

Released: November 13, 2023

Share

Faculty

Beth Faiman

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center
Cleveland, Ohio

Provided by

Provided by Partners for Advancing Clinical Education (PACE)

ProCE Banner

Supporters

Supported by an educational grant from Merck Sharp & Dohme, LLC

Merck Sharp & Dohme, LLC